An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Expanded access; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 05 Oct 2016 Status changed from recruiting to completed.
    • 26 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top